Merck: Jefferies coverage as a buyer
(CercleFinance.com) - Jefferies began to monitor Merck shares on Monday, with a price target of $125 (cp: $103, +1.
8%).
Merck has a better EPS growth profile than its large-cap peers, the analyst says, adding that the company's flagship drug, Keytruda, is poorly valued by investors.
In addition, Sotatercept is "on the rise" and the cardiovascular segment is estimated to have peak sales of $10bn.
Above all, Gardasil has a great growth opportunity in China and stable growth levels in the US, Jefferies notes. It sees the HPV vaccine reaching $11bn by 2030, even continuing to grow beyond that.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
8%).
Merck has a better EPS growth profile than its large-cap peers, the analyst says, adding that the company's flagship drug, Keytruda, is poorly valued by investors.
In addition, Sotatercept is "on the rise" and the cardiovascular segment is estimated to have peak sales of $10bn.
Above all, Gardasil has a great growth opportunity in China and stable growth levels in the US, Jefferies notes. It sees the HPV vaccine reaching $11bn by 2030, even continuing to grow beyond that.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.